secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perceptive Capital Solutions Corp (PCSC)
CIK:        0002017526
Form:       8-K
Filed at:   2026-07-27T12:10:47+00:00
Accession:  0001140361-26-029689
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Freenome's SimpleScreen CRC blood test; Abbott to commercialize, $100M milestone payment triggered
--------------------------------------------------------------------------------

- SimpleScreen CRC detected colorectal cancer with 81.1% sensitivity and 90.4% specificity in the PREEMPT CRC study of over 48,000 patients.
- Freenome receives a $100 million milestone payment from Abbott for FDA approval; Abbott will exclusively commercialize the test in the U.S.
- Test meets Medicare coverage criteria and is expected to be incorporated into American Cancer Society guidelines by name.
- Up to 60 million Americans are overdue for colorectal cancer screening; blood-based test aims to increase screening rates.
- Approval marks first commercial milestone for Freenome's Personalized Cancer Detection platform; company plans to expand SimpleScreen portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2017526/000114036126029689/0001140361-26-029689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2017526/000114036126029689/ef20078829_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-029689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer